Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies.
This cross-sectional study evaluated the association between radiographic evidence of alveolar bone loss and the concentration of host-derived bone resorptive factors (interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6, prostaglandin-E2), and markers of bone turnover [pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin, osteonectin] in stimulated human whole saliva collected from 110 untreated dental patients. Alveolar bone loss scores for each patient were derived from radiographic examination. Variables positively associated with increased bone loss score were: age, current smoking, use of bisphosphonate drugs, and salivary interleukin-1beta levels above the median. Salivary osteonectin levels above the median were associated with a decreased bone loss score. Additional in vitro studies were carried out to determine the fate of interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha added to whole and parotid saliva. All cytokines added to saliva were detected in significantly lower concentrations than when added to buffer alone. Protease inhibitors added to saliva did not prevent the reduction in detection of biomarkers. Variation in time of incubation, repeated cycles of freezing and thawing, or exposure to dimethylsulfoxide did not appreciably affect the measurement of cytokines in saliva. These results suggest that detection of biomarkers by conventional immunoassays may underestimate the actual quantity of molecules in saliva.
Ng
Patricia Yen Bee
PY
Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA.
Donley
Maureen
M
Hausmann
Ernest
E
Hutson
Alan D
AD
Rossomando
Edward F
EF
Scannapieco
Frank A
FA
D000328:Adult; D000367:Age Factors; D000368:Aged; D016301:Alveolar Bone Loss / Q000175:diagnosis* / Q000000981:diagnostic imaging; D015415:Biomarkers / Q000032:analysis*; D024042:Collagen Type I; D003430:Cross-Sectional Studies; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007118:Immunoassay; D008297:Male; D008334:Mandible / Q000000981:diagnostic imaging; D008437:Maxilla / Q000000981:diagnostic imaging; D008875:Middle Aged; D015675:Osteocalcin / Q000032:analysis; D015676:Osteonectin / Q000032:analysis; D010446:Peptide Fragments / Q000032:analysis; D010455:Peptides; D011347:Procollagen / Q000032:analysis; D011859:Radiography; D012307:Risk Factors; D012463:Saliva / Q000737:chemistry*; D012907:Smoking; D013048:Specimen Handling / Q000379:methods
D015415:Biomarkers; D024042:Collagen Type I; D004164:Diphosphonates; D015676:Osteonectin; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin